Pfizer buys Encysive for $195 million
Executive Summary
The acquisition of pulmonary arterial hypertension therapy Thelin manufacturer Encysive could prove to be a bargain based on Thelin's (sitaxsentan) 2008 projected sales of $40 million to $50 million in Europe, where it gained approval in 2006. However, the product has struggled to gain approval in the U.S., drawing three "approvable" letters. A 12-week Phase III trial is planned to provide FDA additional evidence of effectiveness...